Publication Name	World Journal of Diabetes
Manuscript ID	94927
Country	China

Received	2024-03-28 03:32
Peer-Review Started	2024-03-28 03:32
To Make the First Decision
Return for Revision	2024-06-25 03:36
Revised	2024-07-06 03:45
Second Decision	2024-07-15 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-07-15 08:18
Articles in Press	2024-07-15 08:18
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-07-29 01:44
Publish the Manuscript Online	2024-09-26 08:51

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Research & Experimental Medicine
Manuscript Type	Editorial
Article Title	Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy
Manuscript Source	Invited Manuscript
All Author List	Jing Guo, Yi Cao, Qing-Yuan Wu and Lu-Sha Cen
ORCID	Author(s) ORCID Number Lu-Sha Cen http://orcid.org/0000-0001-7223-340X
Funding Agency and Grant Number	Funding Agency Grant Number Scientific Research Project Fundation of Zhejiang Chinese Medical University NO. 2023FSYYZZ01 National Natural Science Foundation of China NO. 82104862
Corresponding Author	Lu-Sha Cen, PhD, Attending Doctor, Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54 Youdian Road, Hangzhou 310006, Zhejiang Province, China. cenlusa2@sina.com
Key Words	Teneligliptin; NLRP3 inflammasome; Diabetes; Diabetic cardiomyopathy; Diabetes complications
Core Tip	Diabetic cardiomyopathy (DCM) is a complication of diabetes, presenting significant challenges in both diagnosis and treatment of DCM. Zhang et al observed the therapeutic effect of teneligliptin on cardiac function in mice with DCM. They confirmed that teneligliptin functions by protecting cardiomyocytes and mitigating inflammation by inhibiting NLRP3 inflammasome activity. This discovery offers clinical management of DCM patients; however, its clinical application necessitates further clinical verification and discussion.
Publish Date	2024-09-26 08:51
Citation	<p>Guo J, Cao Y, Wu QY, Cen LS. Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy. <i>World J Diabetes</i> 2024; 15(10): 2002-2005</p>
URL	https://www.wjgnet.com/1948-9358/full/v15/i10/2002.htm
DOI	https://dx.doi.org/10.4239/wjd.v15.i10.2002

Full Article (PDF)	WJD-15-2002-with-cover.pdf
Manuscript File	94927_Auto_Edited_091657.docx
Answering Reviewers	94927-answering-reviewers.pdf
Audio Core Tip	94927-audio.m4a
Conflict-of-Interest Disclosure Form	94927-conflict-of-interest-statement.pdf
Copyright License Agreement	94927-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	94927-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	94927-non-native-speakers.pdf
Peer-review Report	94927-peer-reviews.pdf
Scientific Misconduct Check	94927-scientific-misconduct-check.png
Scientific Editor Work List	94927-scientific-editor-work-list.pdf
CrossCheck Report	94927-crosscheck-report.png
CrossCheck Report	94927-crosscheck-report.pdf